1-2 of 2
Erik Maquoi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy

Pierre Foidart, Cassandre Yip, Jean Radermacher, Silvia Blacher, Mehdi Lienard, Laetitia Montero-Ruiz, Erik Maquoi, Elodie Montaudon, Sophie Château-Joubert, Joëlle Collignon, Michel Coibion, Véronique Jossa, Elisabetta Marangoni, Agnès Noël, Nor Eddine Sounni, Guy Jerusalem
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1838–1850.
https://doi.org/10.1158/1078-0432.CCR-18-1880
Published: 15 March 2019
View article titled, Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy
Open the PDF for Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy in another window
Includes: Supplementary data
Journal Articles

Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases Inhibitor

Erik Maquoi, Nor Eddine Sounni, Laetitia Devy, Fabrice Olivier, Francis Frankenne, Hans-Willi Krell, Frank Grams, Jean-Michel Foidart, Agnès Noël
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4038–4047.
https://doi.org/10.1158/1078-0432.CCR-04-0125
Published: 24 June 2004
View article titled, Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases Inhibitor
Open the PDF for Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases Inhibitor in another window